REGENXBIO Inc. - Common Stock (RGNX)

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.

They'll join the index before the open on Dec. 23 as part of a quarterly rebalance.

REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS Microinjector and strategic partnerships.

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.